Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate Safety, Pharmacokinetics, and Antiviral Activity of Lenacapavir Administered Subcutaneously in Human Immunodeficiency Virus (HIV) -1 Infected Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 8.0

Eligibility Criteria:
Key Inclusion Criteria:~* Plasma HIV-1 RNA ≥ 5,000 copies/mL but ≤ 400,000 copies/mL and CD4+ cell count \> 200 cells/mm\^3~* Treatment naive or experienced but CAI (for Part A only) and integrase strand transfer inhibitor (INSTI) naïve, and have not received any antiretroviral therapy (ART) within 12 weeks of screening~* Screening genotype report must show sensitivity to B/F/TAF to allow its initiation on Day 10~* Screening genotype report must show sensitivity to at least one agent in either non-nucleoside reverse transcriptase inhibitor (NNRTI) or protease inhibitor (PI) class to allow its use as part of standard of care oral antiretroviral treatment in the future~* Have adequate renal function (estimated glomerular filtration rate ≥ 70 mL/min)~* No clinically significant abnormalities in electrocardiography (ECG) at Screening~* Willing to initiate B/F/TAF on Day 10 after completion of all assessments~Key Exclusion Criteria:~* Pregnant or lactating females~Note: Other protocol defined Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Part A: Lenacapavir 20 mg (Type: EXPERIMENTAL): Participants will receive single dose of lenacapavir 20 mg on Day 1 followed by bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) as per standard-care therapy starting on Day 10 through Day 225.
- Part A: Lenacapavir 50 mg (Type: EXPERIMENTAL): Participants will receive single dose of lenacapavir 50 mg on Day 1 followed by B/F/TAF as per standard-care therapy starting on Day 10 through Day 225.
- Part A: Lenacapavir 150 mg (Type: EXPERIMENTAL): Participants will receive single dose of lenacapavir 150 mg on Day 1 followed by B/F/TAF as per standard-care therapy starting on Day 10 through Day 225.
- Part A: Lenacapavir 450 mg (Type: EXPERIMENTAL): Participants will receive single dose of lenacapavir 450 mg on Day 1 followed by B/F/TAF as per standard-care therapy starting on Day 10 through Day 225.
- Part A: Lenacapavir 750 mg (Type: EXPERIMENTAL): Participants will receive single dose of lenacapavir 750 mg on Day 1 followed by B/F/TAF as per standard-care therapy starting on Day 10 through Day 225.
- Part A: Placebo (Type: PLACEBO_COMPARATOR): Participants will receive single dose of placebo matched to lenacapavir on Day 1 followed by B/F/TAF as per standard-care therapy starting on Day 10 through Day 225.
- Part B: TAF 200 mg (Type: EXPERIMENTAL): Participants will receive a single dose of TAF 200 mg on Day 1 followed by B/F/TAF as per standard-care therapy starting on Day 10 through Day 225.
- Part B: TAF 600 mg (Type: EXPERIMENTAL): Participants will receive a single dose of TAF 600 mg on Day 1 followed by B/F/TAF as per standard-care therapy starting on Day 10 through Day 225.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete